The United Kingdom and the United States have established a key trade agreement that will maintain no duties on British pharmaceutical products entering the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase expenditure on drugs through the public health system. This pledge secures that tariffs on these crucial products will stay at nothing for a period of 36 months.
This agreement comes after previous warnings to hike import taxes on branded drug imports, with increases floated up to one hundred percent.
"This arrangement between the Britain strengthens the worldwide climate for new treatments and brings long-overdue balance to transatlantic drug exports," a statement said.
Economic Importance
Medicines are one of the UK's most significant goods shipped to the United States, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the year leading up to last September, the UK exported medicines totaling billions to the US. This value made up a significant portion of British export trade in that timeframe.
"This guarantee protects employment, increases funding and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister stated.
Detailed UK Commitments
The agreement entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped twenty percent.
Industry Background
The deal takes place against a ongoing tension between the drug companies and the ministers over drug pricing and NHS adoption.
This friction were heightened by arguments that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the previous ten-year period.
